Dr. Julie Gerberding is the executive vice president and chief patient officer at Merck, a multinational pharmaceutical company.
In 2010, Dr. Gerberding joined Merck as the company’s president of vaccines, where she played a significant role in increasing worldwide access to the company’s vaccines. During her time with Merck Dr. Gerberding has built on her passions for addressing disparities within the medical community and advocating for gender parity and advancement of women in the life sciences. She is an executive sponsor of the Merck Women’s Network, mentoring dozens of women inside and outside the company. Additionally, she’s working to improve the rates of maternal mortality through the Merck for Mothers program.
Prior to joining Merck, Dr. Gerberding worked for the U.S. Centers for Disease Control and Prevention (CDC), serving as its director from 2002 to 2009. She was the first woman to hold the position. While there, Dr. Gerberding notably led the country through the anthrax crisis, SARS, bird flu, and 40 other emergency responses. From 1998 to 2002, she worked as the CDC’s divisional director for healthcare quality promotion.
Before her time at the CDC, Dr. Gerberding was a tenured faculty member in infectious diseases at the University of California, San Francisco—an institution she continues to serve to this day as an adjunct associate clinical professor of medicine. During her time in San Francisco, Dr. Gerberding served on the front lines of the city’s emerging AIDS/HIV crisis. She directed the Prevention Epicenter, which focused on preventing infection in patients and their healthcare providers.
Dr. Gerberding serves on a number of committees and boards, including the boards of Cerner Corporation, MSD, CWRU, Wellcome Trust Hilleman Laboratories, and the BIO Executive Committee.
She has received numerous awards and honors for her contributions to the medical community, from being named on Time’s list of “100 Most Influential People” in 2004, to receiving the Healthcare Businesswomen Association’s Woman of the Year award in 2018.
Dr. Gerberding earned both her undergraduate degree and her M.D. at Case Western Reserve University. She also holds her master’s of public health from the University of California, Berkeley, and completed her internship and residency in internal medicine as well as a fellowship in clinical pharmacology and infectious diseases at the University of California, San Francisco.
What is Julie L. Gerberding's net worth?
The estimated net worth of Julie L. Gerberding is at least $5.54 million as of July 17th, 2020. Dr. Gerberding owns 62,862 shares of Merck & Co., Inc. stock worth more than $5,535,502 as of March 27th. This net worth evaluation does not reflect any other assets that Dr. Gerberding may own. Learn More about Julie L. Gerberding's net worth.
How do I contact Julie L. Gerberding?
The corporate mailing address for Dr. Gerberding and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at investor_relations@merck.com. Learn More on Julie L. Gerberding's contact information.
Has Julie L. Gerberding been buying or selling shares of Merck & Co., Inc.?
Julie L. Gerberding has not been actively trading shares of Merck & Co., Inc. in the last ninety days. Most recently, Julie L. Gerberding sold 36,285 shares of the business's stock in a transaction on Friday, July 17th. The shares were sold at an average price of $80.00, for a transaction totalling $2,902,800.00. Following the completion of the sale, the executive vice president now directly owns 62,862 shares of the company's stock, valued at $5,028,960. Learn More on Julie L. Gerberding's trading history.
Who are Merck & Co., Inc.'s active insiders?
Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Cristal Downing (Insider), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Inge Thulin (Director), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.
Are insiders buying or selling shares of Merck & Co., Inc.?
During the last year, Merck & Co., Inc. insiders bought shares 1 times. They purchased a total of 2,833 shares worth more than $250,012.25. During the last year, insiders at the sold shares 1 times. They sold a total of 2,361 shares worth more than $209,562.36. The most recent insider tranaction occured on February, 6th when Director Inge G Thulin bought 2,833 shares worth more than $250,012.25. Insiders at Merck & Co., Inc. own 0.1% of the company.
Learn More about insider trades at Merck & Co., Inc.. Information on this page was last updated on 2/6/2025.
